兽医肾臟疾病市场－全球产业规模、份额、趋势、机会和预测：按类型、动物种类、给药途径、最终用途、地区和竞争格局划分，2021-2031年

全球兽医肾臟疾病市场预计将从 2025 年的 179.9 亿美元成长到 2031 年的 243.7 亿美元，复合年增长率为 5.19%。

该市场涵盖用于检测和治疗家畜及伴侣动物肾功能障碍的治疗药物、诊断设备和特殊营养食品。主要成长要素包括老年宠物慢性肾臟病率的上升以及全球宠物数量的增长。这些因素增加了对持续兽医护理的需求。与短暂的科技潮流不同，这些因素源自于人们对动物更深层的人文关怀，促使饲主投入大量资金来延长宠物的寿命并提高其生活品质。

然而，持续的兽医护理费用仍然是一大障碍。经济拮据往往导致治疗延误或放弃必要的长期肾臟治疗，阻碍了产生收入。美国兽医协会2024年的数据凸显了这个问题，数据显示，美国家庭在兽医护理方面的平均支出比去年同期下降了4%。这一降幅表明，宠物饲主的经济敏感性仍然是全面实施肾臟疾病综合管理策略的主要障碍。

市场驱动因素

慢性肾臟病(CKD) 在老年伴侣动物中的日益普遍，正成为市场成长的主要催化剂，推动兽医通讯协定向早期检测和监测方向的根本性转变。随着综合护理水准的提高延长了犬猫的平均寿命，易受老龄化相关性肾功能衰退影响的动物数量自然增加，因此兽医诊所需要开展更积极主动、更规律的筛检。这种人口结构的变化直接推动了用于识别症状前肾损伤的诊断试剂盒和生物标记的引入。例如，IDEXX Laboratories 在 2024 年 10 月发布的 2024 年第三季财报中指出，其诊断业务的经常性收入实​​现了 7%的内部成长，这主要得益于预防性健康检测的增加以及一系列肾臟疾病管理解决方案的研发。

同时，宠物人性化趋势的日益增强以及医疗保健支出的增加，提升了营养支持和先进肾臟治疗的商业性可行性。饲主越来越将宠物视为家庭成员，导致他们对高端医疗食品和维持生命药物的价格敏感度降低。硕腾（Zoetis）的案例便印证了这一趋势。该公司在2024年11月发布的2024年第三季财报中显示，其伴侣动物产品组合的全球营收成长了15%，显示该公司对动物保健领域的坚定投资。此外，雀巢在2024年7月发布的2024年上半年财报显示，普瑞纳宠物食品（Purina PetCare）的销售额达到约107亿美元，这主要得益于市场对科学配方兽用处方食品的需求。

市场挑战

持续的兽医护理高成本，直接阻碍了全球兽医肾臟疾病市场的成长。肾臟疾病的治疗会带来持续的经济负担，包括反覆的诊断测试、终身服药以及昂贵的治疗性处方粮。这些累积的费用是继续治疗的主要障碍，对价格敏感的饲主往往选择安宁疗护或普通商业食品，而不是昂贵的处方粮。这种消费行为限制了肾臟专科产品的潜在市场，也阻碍了生产商和兽医诊所充分实现其治疗产品组合的获利。

近期数据显示，经济压力影响饲主的决策，凸显了这个经济负担。 2024年，PDSA报告称，“26%的犬饲主表示生活开支影响了他们对宠物的照顾”，这表明许多饲主因费用问题而推迟带宠物就医。这项统计数据表明，经济敏感性已成为一种普遍趋势，导致宠物就医频率降低，肾臟疾病治疗方案的使用量也减少。

市场趋势

将人工智慧 (AI) 整合到肾臟诊断工具中，透过提高肾功能障碍识别的准确性和速度，正在改变兽医肾臟病学。血液和尿液检查平台中的 AI 驱动演算法可自动检测肾臟健康的关键指标—病理成分，例如尿液结晶和输尿管管型。与传统方法相比，这项技术减少了人工判读的差异，并能更早发现肾功能的变化。例如，在 2024 年 12 月题为「硕腾宣布 Vetscan Imagyst 功能增强」的新闻稿中，硕腾宣布了 AI 增强功能，包括可识别特定结晶的高级尿沉渣分析，从而支持数据驱动的即时临床决策。

同时，无论是急性病例或慢性病例，对即时治疗方案调整的需求正推动着肾功能照护现场检测解决方案的显着发展。兽医越来越多地使用先进的院内分析仪即时评估关键肾臟生物标记物，从而最大限度地减少对外部实验室的依赖，并实现当日诊疗。这种能力对于监测肾功能受损患者的水合状态和药物调整至关重要。根据IDEXX Laboratories于2025年2月发布的2024年第四季及全年财报，其院内VetLab耗材实现了12%的有机收入增长，凸显了临床上对快速诊断基础设施的日益青睐，以应对肾臟疾病等复杂病症。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球兽医肾臟疾病市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（诊断、治疗）
  • 动物种类（狗、猫、马、牛、其他）
  • 给药途径（口服、注射）
  • 透过申请（兽医医院/诊所、宠物店、电子商务、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美兽医肾臟疾病市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲兽医肾臟疾病市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区兽医肾臟疾病市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲兽医肾臟疾病市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲兽医肾臟疾病市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球兽医肾臟疾病市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zoetis Inc
• Nestle Purina PetCare
• Mars Inc.
• Hill's Pet Nutrition, Inc.
• The JM Smucker Company
• General Mills Inc.
• Merck & Co., Inc
• Elanco Animal Health Inc.
• Phibro Animal Health Corporation
• Ceva Sante Animale

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Veterinary Renal Disease Market is projected to expand from USD 17.99 Billion in 2025 to USD 24.37 Billion by 2031, reflecting a compound annual growth rate of 5.19%. This market encompasses therapeutic pharmaceuticals, diagnostic instruments, and specialized dietary formulations aimed at detecting and managing kidney dysfunction in livestock and companion animals. Key growth drivers include the rising incidence of chronic kidney disease within aging pet populations and increased global pet adoption, which fuels the need for consistent veterinary care. Unlike fleeting technological fads, these drivers are rooted in the profound humanization of animals, motivating owners to invest substantially in prolonging their pets' lives and enhancing their quality of life.

However, the market encounters significant obstacles related to the affordability of continuous veterinary care. Financial limitations often result in deferred treatments or the refusal of essential long-term renal therapies, which hinders revenue generation. Data from the 'American Veterinary Medical Association' in '2024' highlights this issue, showing a 4% decrease in the average household expenditure on veterinary care compared to the prior year. This decline suggests that financial sensitivity among pet owners persists as a major barrier to the broad implementation of comprehensive renal disease management strategies.

Market Driver

The increasing prevalence of chronic kidney disease (CKD) among aging companion animals acts as a major catalyst for market growth, prompting a fundamental shift in veterinary protocols toward early detection and monitoring. As improved general care extends the life expectancies of dogs and cats, the population vulnerable to age-related renal degeneration naturally grows, necessitating more aggressive routine screening in veterinary clinics. This demographic evolution directly fuels the adoption of diagnostic panels and biomarkers required to identify kidney dysfunction prior to symptom onset. For instance, IDEXX Laboratories reported in their 'Third Quarter 2024 Financial Results' from October 2024 that diagnostics recurring revenue saw a 7% organic growth, driven by volume gains in preventative care testing, creating a pipeline for renal disease management solutions.

Concurrently, the rising trend of pet humanization and increased healthcare spending boosts the commercial viability of nutritional support and advanced renal therapies. Owners increasingly regard pets as family members, reducing price sensitivity toward premium medical diets and life-extending pharmaceutical treatments. This is evidenced by Zoetis, which reported in November 2024's 'Third Quarter 2024 Financial Results' that operational revenue for their companion animal portfolio rose by 15% globally, highlighting strong investment in animal health. Furthermore, Nestle's 'Half-Year Results 2024' from July 2024 indicated that Purina PetCare sales hit approximately $10.7 billion, driven significantly by the demand for science-based veterinary formulations.

Market Challenge

The high cost of ongoing veterinary care presents a direct obstacle to the growth of the Global Veterinary Renal Disease Market. Managing kidney disease requires a sustained financial commitment involving repeated diagnostic testing, lifelong medication, and premium therapeutic diets. These cumulative costs create significant adherence barriers; consequently, price-sensitive owners often choose palliative care or standard commercial foods over expensive prescription formulations. Such consumer behavior restricts the addressable market for specialized renal products, limiting the ability of manufacturers and clinics to fully capitalize on their therapeutic portfolios.

This financial strain is emphasized by recent data highlighting the economic pressures affecting owner decision-making. In '2024', the 'PDSA' reported that '26% of dog owners indicated that the cost of living affected their ability to care for their pets', with many delaying veterinary visits due to expense. This statistic underscores that economic sensitivity is a prevailing trend that diminishes the frequency of veterinary interventions and reduces the consumption of renal disease management solutions.

Market Trends

The integration of Artificial Intelligence into renal diagnostic tools is transforming veterinary nephrology by improving the accuracy and speed of identifying kidney dysfunction. AI-driven algorithms within hematology and urinalysis platforms now automate the detection of pathological elements, such as urinary crystals and casts, which are vital indicators of renal health. This technology reduces manual interpretation variability and allows for earlier detection of kidney function changes compared to traditional methods. For example, in a December 2024 press release titled 'Zoetis to Expand Vetscan Imagyst Capabilities', Zoetis announced AI-powered enhancements including advanced urine sediment analysis to identify specific crystals, facilitating immediate, data-driven clinical decisions.

Simultaneously, there is a marked shift toward point-of-care renal function testing solutions, driven by the need for immediate treatment adjustments in both acute and chronic cases. Veterinarians are increasingly utilizing advanced in-clinic analyzers that offer real-time assessments of key renal biomarkers, thereby minimizing reliance on reference laboratories and enabling same-day management. This capability is crucial for monitoring fluid and medication adjustments in renally compromised patients. According to IDEXX Laboratories' 'Fourth Quarter and Full Year 2024 Results' from February 2025, in-clinic VetLab consumables achieved 12% organic revenue growth, underscoring the rising clinical preference for rapid diagnostic infrastructure to manage complex conditions like renal disease.

Key Market Players

• Zoetis Inc
• Nestle Purina PetCare
• Mars Inc.
• Hill's Pet Nutrition, Inc.
• The J.M. Smucker Company
• General Mills Inc.
• Merck & Co., Inc
• Elanco Animal Health Inc.
• Phibro Animal Health Corporation
• Ceva Sante Animale

Report Scope

In this report, the Global Veterinary Renal Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Renal Disease Market, By Type

• Diagnosis
• Treatment

Veterinary Renal Disease Market, By Animal type

• Canine
• Feline
• Equine
• Bovine
• Others

Veterinary Renal Disease Market, By Route of Administration

• Oral
• Injectable

Veterinary Renal Disease Market, By End Use

• Veterinary Hospitals & Clinics
• Pet Specialty Stores
• E-commerce
• Others

Veterinary Renal Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Renal Disease Market.

Available Customizations:

Global Veterinary Renal Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Renal Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Diagnosis, Treatment)
  • 5.2.2. By Animal type (Canine, Feline, Equine, Bovine, Others)
  • 5.2.3. By Route of Administration (Oral, Injectable)
  • 5.2.4. By End Use (Veterinary Hospitals & Clinics, Pet Specialty Stores, E-commerce, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Renal Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Animal type
  • 6.2.3. By Route of Administration
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Renal Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Animal type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Veterinary Renal Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Animal type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Veterinary Renal Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Animal type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End Use

7. Europe Veterinary Renal Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Animal type
  • 7.2.3. By Route of Administration
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Renal Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Animal type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Veterinary Renal Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Animal type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Veterinary Renal Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Animal type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Veterinary Renal Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Animal type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Veterinary Renal Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Animal type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End Use

8. Asia Pacific Veterinary Renal Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Animal type
  • 8.2.3. By Route of Administration
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Renal Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Animal type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Veterinary Renal Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Animal type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Veterinary Renal Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Animal type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Veterinary Renal Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Animal type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Veterinary Renal Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Animal type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Veterinary Renal Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Animal type
  • 9.2.3. By Route of Administration
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Renal Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Animal type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Veterinary Renal Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Animal type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Veterinary Renal Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Animal type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End Use

10. South America Veterinary Renal Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Animal type
  • 10.2.3. By Route of Administration
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Renal Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Animal type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Veterinary Renal Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Animal type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Veterinary Renal Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Animal type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Renal Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Nestle Purina PetCare
• 15.3. Mars Inc.
• 15.4. Hill's Pet Nutrition, Inc.
• 15.5. The J.M. Smucker Company
• 15.6. General Mills Inc.
• 15.7. Merck & Co., Inc
• 15.8. Elanco Animal Health Inc.
• 15.9. Phibro Animal Health Corporation
• 15.10. Ceva Sante Animale

16. Strategic Recommendations

17. About Us & Disclaimer